| abstract |
A method of treating a cognitive or neurodegenerative disease, wherein a patient in need of such treatment is combined with an effective amount of an anti-tau antibody to an effective amount of an anti-N3pGluAbeta antibody, anti-Abeta antibody, or amyloid beta. Administering an antibody fragment that is bound and covalently bound to a polyethylene glycol molecule. |